# Embolization Particle Market

> Embolization Particle Market Research Report: Information By Product Type (Radioembolization and Drug Eluting Beads), By Application (Oncology, Peripheral Vascular Disease, Neurology), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 12.21%
- **2024:** $ 0.78 Billion
- **2025:** $ 0.88 Billion
- **2035:** $ 2.77 Billion
- **Key Players:** Boston Scientific (US), Medtronic (US), Terumo Corporation (JP), Merit Medical Systems (US), AngioDynamics (US), Cook Medical (US), Stryker Corporation (US), B. Braun Melsungen AG (DE), Asahi Intecc (JP)

**Report ID:** MRFR/Pharma/3388-CR · **Pages:** 113 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/embolization-particle-market-4815

---

## Market Summary

## **Global Embolization Particle Market Overview**

The Embolization Particle Market Size was valued at USD 0.69 Billion in 2023. The Embolization Particle market industry is projected to grow from USD 0.78 Billion in 2024 to USD 1.98 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.21% during the forecast period (2024 - 2032). The rise of treatments that don’t cut into the body too much and many heart disease cases are the key market drivers enhancing market growth.

Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review

## **Embolization Particle Market Trends**

### **Growing prevalence of cancer incidence is driving the market growth**

Market CAGR for embolization particles is driven by the rising rates of cancer because particle embolization is an important advancement for the treatment of cancer and other malignancies. The increasing worldwide cancer incidence has influenced the development of the Embolization Particle industry. They are increasingly used to treat illnesses apart from cancer, such as vascular abnormalities and fibrosis. The market is being bolstered by factors such as the rapidly growing healthcare sector and the increasing attention paid by academic institutions to developing cutting-edge technological solutions for improved diagnostics and treatment modalities.

Demand for embolization particles is expected to rise due to the issues mentioned above in the future.

Additionally, [minimally invasive](../../../reports/minimally-invasive-cosmetic-procedures-market-5923) methods, such as embolization particle therapy, are gaining popularity among patients and medical professionals, which bodes well for the future of the market for related products. The rise in cancer rates worldwide and the introduction of new types of Embolization Particles are factors that should help the market expand in the next years. Moreover, leading companies continually release cutting-edge, highly efficient products, which contributes to developing the embolization particle market. The embolization cancer market is anticipated to expand in the coming years due to increasing expenditure on research and development and industry leaders’ introduction of new products.

Governments and non-profit organizations are trying to raise public awareness of embolization cancer in some countries. Oncologists and other cancer specialists have recently been interested in embolization cancer research. Therefore, the increasing prevalence of embolization particles is fueling the expansion of the international market. For instance, Guerbet (FR0000032526 GBT) reports it's going more than treble its line of microcatheters and introducing a new line of guidewires, resulting in a wide range of interventional imaging and embolization solutions being offered.

As a result, the demand for embolization particles is predicted to grow throughout the forecasted time due to the rising cancer cases. Thus, the driving factor is the embolization particle market revenue.

## **Embolization Particle Market Segment Insights**

### **Embolization Particle Product Type Insights**

The embolization particle market segmentation, based on product type, includes radioembolization and drug-eluting beads. In 2022, the radioembolization segment led the embolization particle market in revenue because of their use in cancer therapy and aids in reducing the rate at which the disease progresses and relieving the symptoms it causes.

**Figure 1: Embolization Particle Market by Application, 2022 & 2032 (USD Billion)** 

_Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review_

### **Embolization Particle Application Insights**

The embolization particle market segmentation, based on application, includes oncology, peripheral vascular disease, and neurology. The oncology is anticipated to grow at a CAGR of 14.20% over the projected period, making up the largest market share. An oncologist is a medical professional that has chosen to focus their career on treating cancer. There are numerous subtypes of oncologists. These doctors can treat patients with cancer in many different parts of the body.

### **Embolization Particle Regional Insights**

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American embolization particle market will dominate Due to the strong economy, the huge growth of the healthcare field, the rise in the number of people with cancer, and the fact that research institutions are putting more and more effort into updating technology to find new and better ways to diagnose and treat people. The market is also growing because hospitals have different layouts, and there are a lot of skilled healthcare workers.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: EMBOLIZATION PARTICLEMARKET SHARE BY REGION 2022 (USD Billion)** 

_Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review_

Europe’s embolization particle market accounts for the second-largest market share because of developments in healthcare provision, which have improved patients' access to diagnosis and treatment, and because of increased consumer knowledge of the medicines offered. Further, the embolization particle market held the largest market share, and the UK embolization particle market was the fastest-growing market in the European region.

 The Asia-Pacific embolization particle market is expected to grow at the fastest CAGR from 2023 to 2032 because more people need healthcare in developing countries like India. In addition, the government's focus on improving healthcare facilities and the surge in [medical tourism](../../../reports/medical-tourism-market-1975) is likely to fuel the expansion of the embolization particle market in this region. Moreover, China’s embolization particle market held the largest market share, and the Indian embolization particle market was the fastest-rising market in the Asia-Pacific region.

## **Embolization Particle Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development to expand their product lines, which will help the embolization particle market grow even more. There are some strategies for action that market participants are implementing to increase their presence around the world's footprint, with important market developments including new product launches, contractual agreements and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the embolization particle industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturer use in the embolization particle industry to benefit clients and increase the market sector. In recent years, the embolization particle industry has offered some of the most significant technological advancements. Major players in the Embolization Particle market, including Guerbet, Terumo, BTG International Ltd, Boston Scientific Corporation, Medtronic, Sirtex, Merit Medical, and others, are attempting to grow market demand by investing in research and development operations.

Terumo has dedicated 100 years to “Contributing to Society through Healthcare” and is a leader in medical technology worldwide. With its headquarters in Tokyo and offices worldwide, Terumo employs more than 30,000 people to offer cutting-edge medical solutions in more than 160 nations and territories. The company has supported healthcare since its beginnings as a Japanese thermometer producer. Its broad range of goods now includes peritoneal dialysis treatments, blood transfusion systems, diabetic care, and solutions for vascular intervention and cardio surgery. It also includes technologies for blood transfusion and cell therapy.

The Cardiac and Vascular Company focuses on treating illnesses of the blood vessels throughout the body, including the vital organs of the heart and lungs. They offer oxygenators and heart-lung machines to maintain life in place of the heart and lungs during cardiac surgery, surgical grafts and stent-grafts to replace blood vessels damaged by disease, and interventional devices that allow treatment by accessing blood vessels through a catheter to treat regions of the body including the heart and brain. Terumo will continue to work to improve its value to patients, healthcare workers, and the general public.

In January 2023, Terumo Corporation (TSE: 4543) and Kyowa Kirin Co., Ltd. (TSE: 4151) collaborated to create the drug-device combination product "G-Lasta® Subcutaneous Injection 3.6 mg BodyPod".

Merit Medical Systems, Inc., a prominent producer, and distributor of unique disposable medical devices used in interventional, diagnostic, and therapeutic procedures, especially in cardiology, radiology, cancer, critical care, and endoscopy, was founded in 1987. Merit provides services to client hospitals worldwide with a domestic and international sales force and a clinical support team of more than 500 people, with offices in South Jordan, Utah. Pearland, Texas; Richmond, Virginia.

Aliso Viejo, California, Maastricht and Venlo, The Netherlands, Paris, France, Galway, Ireland, Beijing, China, Tijuana, Mexico, Joinville, Brazil, Ontario, Canada, Melbourne, Australia, Tokyo, Japan, Reading, the United Kingdom, Johannesburg, South Africa, and Singapore, Merit employs about 6,300 people worldwide.

To build long-term value for our customers, employees, shareholders, and communities, we must be outwardly focused and committed to providing an unforgettable experience. In March 2023, Merit Medical Systems announced that the SwiftNINJA Steerable Microcatheter product line had been widened. There are new lengths of 150 cm and a 2.4F distal diameter option with a low profile.

### **Key Companies in the Embolization Particle Market include**

- Guerbet
- Terumo
- BTG International Ltd
- Boston Scientific Corporation
- [Medtronic](https://www.medtronic.com/me-en/healthcare-professionals/products/neurological/avm-embolization.html)
- Sirtex
- Merit Medical

## **Embolization Particle Industry Developments**

- **Q2 2024: Boston Scientific Announces FDA Approval of Embold™ Fibered Detachable Coil for Peripheral Embolization** Boston Scientific received FDA approval for its Embold™ Fibered Detachable Coil, expanding its embolization portfolio for peripheral vascular procedures. The device is designed to offer precise placement and effective occlusion in a range of embolization applications.
- **Q1 2024: Merit Medical Launches EmboCube™ Embolization Gelatin in Europe** Merit Medical announced the European launch of EmboCube™, a gelatin-based embolization product intended for use in controlling bleeding and in various embolization procedures. The product launch expands Merit’s presence in the European interventional radiology market.
- **Q2 2024: Terumo Receives CE Mark for HydroPearl® Microspheres for Embolization** Terumo Corporation received CE Mark approval for its HydroPearl® Microspheres, enabling commercialization of the embolization product across the European Union for the treatment of hypervascular tumors and uterine fibroids.
- **Q1 2024: Sirtex Medical Announces Strategic Partnership with Magle Chemoswed for Novel Embolization Microspheres** Sirtex Medical entered a strategic partnership with Magle Chemoswed to co-develop and commercialize novel embolization microspheres, aiming to enhance treatment options for interventional oncology and other embolization procedures.
- **Q2 2024: Shape Memory Medical Receives FDA Clearance for IMPEDE-FX Embolization Plug** Shape Memory Medical announced FDA clearance for its IMPEDE-FX Embolization Plug, a device designed to occlude blood vessels in peripheral vasculature, expanding the company’s embolization product offerings in the U.S. market.
- **Q1 2024: Embolx Announces First Patient Treated with Sniper® Balloon Occlusion Microcatheter in Japan** Embolx reported the first clinical use of its Sniper® Balloon Occlusion Microcatheter in Japan, marking a milestone in the company’s international expansion and the adoption of its technology for targeted embolization procedures.
- **Q2 2024: BTG Launches DC Bead LUMI™ Radiopaque Embolic Bead in Canada** BTG, now part of Boston Scientific, launched the DC Bead LUMI™ radiopaque embolic bead in Canada, providing interventional radiologists with enhanced visualization during embolization procedures for liver cancer and other indications.
- **Q1 2024: Terumo Opens New Manufacturing Facility for Embolization Products in Vietnam** Terumo Corporation inaugurated a new manufacturing facility in Vietnam dedicated to the production of embolization particles and related devices, aiming to meet growing global demand and improve supply chain resilience.
- **Q2 2024: Boston Scientific Completes Acquisition of Obsidio, Inc.** Boston Scientific completed the acquisition of Obsidio, Inc., a company specializing in novel hydrogel embolization technology, strengthening its portfolio in the interventional oncology and embolization market.
- **Q1 2024: Merit Medical Receives FDA Clearance for Embosphere® Microspheres for Prostatic Artery Embolization** Merit Medical received FDA clearance for an expanded indication of its Embosphere® Microspheres, now approved for use in prostatic artery embolization to treat benign prostatic hyperplasia.
- **Q2 2024: Sirtex Medical Announces Appointment of New CEO** Sirtex Medical appointed a new Chief Executive Officer to lead the company’s global expansion and drive innovation in the embolization particle sector.
- **Q1 2024: Embolx Raises $15 Million in Series C Funding to Accelerate Embolization Technology Development** Embolx secured $15 million in Series C funding to support the development and commercialization of its next-generation embolization devices, with a focus on expanding clinical applications and global reach.

## **Embolization Particle Market Segmentation**

### **Embolization Particle Product Type Outlook**

- Radioembolization
- Drug Eluting Beads

### **Embolization Particle Application Outlook**

- Oncology
- Peripheral Vascular Disease
- Neurology

### **Embolization Particle Regional Outlook**

## Market Drivers

### Rising Geriatric Population

The aging population is a significant driver of the Embolization Particle Market. As individuals age, they become more susceptible to various health issues, including those that require embolization procedures. The United Nations projects that the number of people aged 65 and older will continue to rise, leading to an increased demand for medical interventions. This demographic shift suggests that healthcare systems will need to adapt to accommodate the growing number of elderly patients requiring embolization therapies. Consequently, the Embolization Particle Market is likely to see sustained growth as it addresses the needs of this expanding patient population.

### Advancements in Medical Technology

Technological innovations are playing a pivotal role in the Embolization Particle Market. The development of advanced embolization particles, such as those with enhanced biocompatibility and targeted delivery capabilities, is driving market growth. Recent advancements in imaging techniques and particle design have improved the efficacy of embolization procedures. For example, the introduction of biodegradable particles has shown promise in reducing complications and improving patient recovery times. As these technologies continue to evolve, they are expected to attract more healthcare providers to adopt embolization techniques, thereby bolstering the Embolization Particle Market.

### Increasing Prevalence of Chronic Diseases

The Embolization Particle Market is experiencing growth due to the rising incidence of chronic diseases such as cancer, cardiovascular disorders, and liver diseases. These conditions often require embolization procedures for effective treatment. For instance, the World Health Organization indicates that cancer cases are projected to rise significantly, leading to an increased demand for embolization therapies. As healthcare providers seek innovative solutions to manage these diseases, the need for embolization particles becomes more pronounced. This trend suggests that the Embolization Particle Market will likely expand as more patients require targeted therapies that utilize these particles for improved outcomes.

### Regulatory Support for Innovative Medical Solutions

The Embolization Particle Market is benefiting from favorable regulatory environments that encourage the development and approval of new medical technologies. Regulatory bodies are increasingly streamlining the approval processes for embolization products, which facilitates quicker access to market for innovative solutions. This trend is particularly evident in regions where healthcare systems are prioritizing advanced treatment options for chronic diseases. As regulations become more supportive, manufacturers are likely to invest in research and development, further propelling the growth of the Embolization Particle Market.

### Growing Awareness and Acceptance of Minimally Invasive Procedures

There is a notable shift towards minimally invasive procedures within the Embolization Particle Market. Patients and healthcare professionals are increasingly recognizing the benefits of these techniques, which include reduced recovery times and lower risk of complications. According to recent surveys, a significant percentage of patients prefer minimally invasive options over traditional surgical methods. This growing acceptance is likely to drive demand for embolization procedures, as they are often performed using these less invasive techniques. Consequently, the Embolization Particle Market is poised for growth as more patients seek out these innovative treatment options.

## Future Outlook

The Embolization Particle Market is projected to grow at a 12.21% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of vascular diseases, and rising demand for minimally invasive procedures.

**New opportunities:**

- Development of biodegradable embolization particles for enhanced patient safety.
- Expansion into emerging markets with tailored product offerings.
- Strategic partnerships with healthcare providers for integrated treatment solutions.

By 2035, the Embolization Particle Market is expected to achieve substantial growth, solidifying its position as a key player in the medical device industry.

## Segment Insights

### By Product Type: Radioembolization (Largest) vs. Drug Eluting Beads (Fastest-Growing)

In the Embolization Particle Market, Radioembolization holds a significant market share due to its widespread adoption in treating various malignancies. This method utilizes radioactive particles to target tumors selectively, thus integrating treatment with imaging capabilities. On the other hand, Drug Eluting Beads, which release[chemotherapy](https://www.marketresearchfuture.com/reports/chemotherapy-market-5791) drugs directly into the tumor, are gaining momentum. This innovative approach appeals to clinicians seeking to enhance therapeutic effectiveness while minimizing systemic side effects, thereby increasing its market presence.

Radioembolization (Dominant) vs. Drug Eluting Beads (Emerging)

Radioembolization is the dominant technique in the Embolization Particle Market, known for its efficacy in selectively irradiating tumors. Its established role in clinical practice and proven success in oncology has bolstered its position as the preferred choice among healthcare providers. Meanwhile, Drug Eluting Beads, labeled as an emerging technology, are rapidly gaining traction due to their ability to localize treatment and reduce the burden of systemic toxicity. The versatility of these beads in treating various tumor types and their adaptability in combination therapies positions them as a significant player in future market developments, catering to a growing need for targeted cancer therapies.

### By Application: Oncology (Largest) vs. Peripheral Vascular Disease (Fastest-Growing)

In the Embolization Particle Market, the application segment is primarily driven by oncology, which holds the largest market share. This segment is crucial for treating various types of tumors, including hepatic, renal, and pulmonary cancers. Peripheral vascular disease follows as a significant contributor, rapidly increasing due to the rising global prevalence of cardiovascular conditions, highlighting the urgent demand for effective treatment options. Neurology, although essential, represents a smaller share, focusing on conditions such as arteriovenous malformations and hemorrhagic strokes, reflecting its specialized niche within the market.

Oncology: Dominant vs. Peripheral Vascular Disease: Emerging

Oncology stands as the dominant application in the Embolization Particle Market, essential for treatment protocols that target tumor tissues effectively using particles for targeted embolization. This approach enhances therapeutic outcomes by minimizing damage to surrounding healthy tissues. Meanwhile, Peripheral Vascular Disease emerges as a rapidly growing segment, fueled by increasing awareness of cardiovascular health and technological advancements in particle-based treatments. Both segments are closely tied to ongoing research and development initiatives aimed at creating more effective embolic agents, with oncology leading in established methodologies while peripheral vascular disease adopts innovative solutions to enhance patient outcomes.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is the largest market for embolization particles, accounting for approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of chronic diseases, and a strong focus on research and development. Regulatory support from agencies like the FDA further catalyzes innovation and adoption of new technologies, enhancing market dynamics. The United States leads the North American market, with significant contributions from key players such as Boston Scientific, Medtronic, and AngioDynamics. The competitive landscape is characterized by continuous product innovations and strategic partnerships. Canada also plays a vital role, with increasing investments in healthcare technology and a growing demand for minimally invasive procedures, contributing to the overall market growth.

### Europe : Emerging Market with Growth Potential

Europe is the second-largest market for embolization particles, holding around 30% of the global market share. The region's growth is propelled by an aging population, rising healthcare expenditures, and increasing awareness of minimally invasive procedures. Regulatory frameworks, such as the Medical Device Regulation (MDR), are enhancing product safety and efficacy, thereby boosting market confidence and adoption rates. Leading countries in Europe include Germany, France, and the UK, where key players like B. Braun Melsungen AG and Terumo Corporation are actively expanding their market presence. The competitive landscape is marked by collaborations and mergers aimed at enhancing product offerings. The region is witnessing a surge in demand for innovative embolization solutions, driven by advancements in medical technology and patient-centric healthcare approaches.

### Asia-Pacific : Rapidly Growing Market Segment

Asia-Pacific is witnessing rapid growth in the embolization particle market, accounting for approximately 20% of the global share. The region's expansion is driven by increasing healthcare investments, rising incidences of cancer and cardiovascular diseases, and a growing preference for minimally invasive procedures. Government initiatives to improve healthcare infrastructure and access to advanced medical technologies are also significant growth catalysts. Countries like Japan, China, and India are leading the market, with key players such as Terumo Corporation and Asahi Intecc making substantial contributions. The competitive landscape is evolving, with local manufacturers emerging alongside established global players. The region's diverse healthcare needs and increasing patient awareness are further propelling the demand for innovative embolization solutions, making it a focal point for market growth.

### Middle East and Africa : Untapped Market with Opportunities

The Middle East and Africa region represents an emerging market for embolization particles, holding about 5% of the global market share. The growth is driven by increasing healthcare investments, rising awareness of advanced medical technologies, and a growing prevalence of chronic diseases. Government initiatives aimed at improving healthcare access and quality are also contributing to market expansion, creating opportunities for new entrants and established players alike. Countries like South Africa, UAE, and Saudi Arabia are at the forefront of this market, with a growing number of healthcare facilities adopting advanced embolization techniques. The competitive landscape is characterized by a mix of local and international players, with increasing collaborations and partnerships aimed at enhancing product offerings. The region's unique healthcare challenges present significant opportunities for innovative solutions in the embolization particle market.

## Competitive Benchmarking

The Embolization Particle Market is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for minimally invasive procedures. Key players such as Boston Scientific (US), Medtronic (US), and Terumo Corporation (JP) are strategically positioned to leverage innovation and expand their market presence. Boston Scientific (US) focuses on enhancing its product portfolio through continuous research and development, while Medtronic (US) emphasizes strategic partnerships to bolster its distribution channels. Terumo Corporation (JP) appears to be concentrating on regional expansion, particularly in emerging markets, thereby shaping a competitive environment that is increasingly collaborative yet fiercely competitive.
In terms of business tactics, companies are localizing manufacturing to reduce costs and optimize supply chains, which is particularly crucial in the context of global economic fluctuations. The market structure is moderately fragmented, with several players vying for market share, yet the collective influence of major companies like AngioDynamics (US) and Merit Medical Systems (US) is notable. These companies are not only competing on product quality but also on the efficiency of their supply chains, which is becoming a critical factor in maintaining competitive advantage.
In August 2025, AngioDynamics (US) announced a strategic partnership with a leading healthcare technology firm to enhance its embolization particle offerings. This collaboration is expected to integrate advanced imaging technologies into their products, potentially improving patient outcomes and operational efficiencies. Such strategic moves indicate a shift towards more integrated solutions in the embolization space, aligning with broader trends in healthcare technology.
In September 2025, Merit Medical Systems (US) launched a new line of embolization particles designed for targeted delivery in complex vascular procedures. This product introduction not only reflects the company’s commitment to innovation but also positions it to capture a larger share of the market by addressing specific clinical needs. The strategic importance of this launch lies in its potential to differentiate Merit Medical in a crowded marketplace, emphasizing the role of tailored solutions in driving competitive advantage.
In July 2025, Terumo Corporation (JP) expanded its manufacturing capabilities in Southeast Asia, aiming to enhance its production efficiency and meet the growing demand in the region. This move is indicative of a broader trend where companies are investing in local production facilities to mitigate supply chain risks and improve responsiveness to market needs. Such expansions are likely to strengthen Terumo’s competitive position in the global market.
As of October 2025, the Embolization Particle Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence in product development. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, underscoring the importance of agility in a rapidly changing market.

## Recent News & Developments

- **Q2 2024: Boston Scientific Announces FDA Approval of Embold™ Fibered Detachable Coil for Peripheral Embolization** Boston Scientific received FDA approval for its Embold™ Fibered Detachable Coil, expanding its embolization portfolio for peripheral vascular procedures. The device is designed to offer precise placement and effective occlusion in a range of embolization applications.
- **Q1 2024: Merit Medical Launches EmboCube™ Embolization Gelatin in Europe** Merit Medical announced the European launch of EmboCube™, a gelatin-based embolization product intended for use in controlling bleeding and in various embolization procedures. The product launch expands Merit’s presence in the European interventional radiology market.
- **Q2 2024: Terumo Receives CE Mark for HydroPearl® Microspheres for Embolization** Terumo Corporation received CE Mark approval for its HydroPearl® Microspheres, enabling commercialization of the embolization product across the European Union for the treatment of hypervascular tumors and uterine fibroids.
- **Q1 2024: Sirtex Medical Announces Strategic Partnership with Magle Chemoswed for Novel Embolization Microspheres** Sirtex Medical entered a strategic partnership with Magle Chemoswed to co-develop and commercialize novel embolization microspheres, aiming to enhance treatment options for interventional oncology and other embolization procedures.
- **Q2 2024: Shape Memory Medical Receives FDA Clearance for IMPEDE-FX Embolization Plug** Shape Memory Medical announced FDA clearance for its IMPEDE-FX Embolization Plug, a device designed to occlude blood vessels in peripheral vasculature, expanding the company’s embolization product offerings in the U.S. market.
- **Q1 2024: Embolx Announces First Patient Treated with Sniper® Balloon Occlusion Microcatheter in Japan** Embolx reported the first clinical use of its Sniper® Balloon Occlusion Microcatheter in Japan, marking a milestone in the company’s international expansion and the adoption of its technology for targeted embolization procedures.
- **Q2 2024: BTG Launches DC Bead LUMI™ Radiopaque Embolic Bead in Canada** BTG, now part of Boston Scientific, launched the DC Bead LUMI™ radiopaque embolic bead in Canada, providing interventional radiologists with enhanced visualization during embolization procedures for liver cancer and other indications.
- **Q1 2024: Terumo Opens New Manufacturing Facility for Embolization Products in Vietnam** Terumo Corporation inaugurated a new manufacturing facility in Vietnam dedicated to the production of embolization particles and related devices, aiming to meet growing global demand and improve supply chain resilience.
- **Q2 2024: Boston Scientific Completes Acquisition of Obsidio, Inc.** Boston Scientific completed the acquisition of Obsidio, Inc., a company specializing in novel hydrogel embolization technology, strengthening its portfolio in the interventional oncology and embolization market.
- **Q1 2024: Merit Medical Receives FDA Clearance for Embosphere® Microspheres for Prostatic Artery Embolization** Merit Medical received FDA clearance for an expanded indication of its Embosphere® Microspheres, now approved for use in prostatic artery embolization to treat benign prostatic hyperplasia.
- **Q2 2024: Sirtex Medical Announces Appointment of New CEO** Sirtex Medical appointed a new Chief Executive Officer to lead the company’s global expansion and drive innovation in the embolization particle sector.
- **Q1 2024: Embolx Raises $15 Million in Series C Funding to Accelerate Embolization Technology Development** Embolx secured $15 million in Series C funding to support the development and commercialization of its next-generation embolization devices, with a focus on expanding clinical applications and global reach.

## Report Scope

| MARKET SIZE 2024 | 0.78(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.8753(USD Billion) |
| MARKET SIZE 2035 | 2.77(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 12.21% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Market analysis in progress |
| Segments Covered | Market segmentation analysis in progress |
| Key Market Opportunities | Advancements in biocompatible materials enhance efficacy in the Embolization Particle Market. |
| Key Market Dynamics | Rising demand for minimally invasive procedures drives innovation and competition in the embolization particle market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Embolization Particle Market by 2035?**
A: The Embolization Particle Market is projected to reach a valuation of 2.77 USD Billion by 2035.

**Q: What was the market valuation of the Embolization Particle Market in 2024?**
A: In 2024, the Embolization Particle Market had a valuation of 0.78 USD Billion.

**Q: What is the expected CAGR for the Embolization Particle Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Embolization Particle Market during the forecast period 2025 - 2035 is 12.21%.

**Q: Which product types are included in the Embolization Particle Market segments?**
A: The product types in the Embolization Particle Market include Radioembolization and Drug Eluting Beads.

**Q: What are the projected valuations for Radioembolization and Drug Eluting Beads by 2035?**
A: By 2035, Radioembolization is projected to reach 1.43 USD Billion, while Drug Eluting Beads is expected to reach 1.34 USD Billion.

**Q: What applications are driving growth in the Embolization Particle Market?**
A: The key applications driving growth in the Embolization Particle Market include Oncology, Peripheral Vascular Disease, and Neurology.

**Q: What are the projected market valuations for Oncology, Peripheral Vascular Disease, and Neurology by 2035?**
A: By 2035, Oncology is projected to reach 1.1 USD Billion, Peripheral Vascular Disease is expected to reach 0.9 USD Billion, and Neurology is anticipated to reach 0.77 USD Billion.

**Q: Who are the key players in the Embolization Particle Market?**
A: Key players in the Embolization Particle Market include Boston Scientific, Medtronic, Terumo Corporation, and Merit Medical Systems.

**Q: How does the growth of the Embolization Particle Market compare to its valuation in 2024?**
A: The market is expected to grow from 0.78 USD Billion in 2024 to 2.77 USD Billion by 2035, indicating substantial growth.

**Q: What factors contribute to the growth of the Embolization Particle Market?**
A: Factors contributing to the growth of the Embolization Particle Market include advancements in medical technology and increasing prevalence of targeted therapies.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/embolization-particle-market-4815*